Jule Vasquez, MD

Thank you OncoDaily for sharing.

One of the most critical aspects of modern care for myeloma patients is providing adequate IgG replacement, particularly for those treated with bispecific antibodies and CAR-Ts. My thoughts and recommendations are below. rafaelfonseca.substack.com/publish/post/1…

Exciting update from @ASCO & @ConquerCancerFd! The LIFe Award has been revised — now supporting 2 fellows (6 months in-person + virtual mentorship up to 18 months). Grateful to contribute through the International Affairs Committee (IAC). 👉 Learn more: asco.org/career-develop…

Honored to be the first Peruvian member of ASCO’s International Affairs Committee (IAC)! Attended the quarterly meeting at ASCO HQ in Virginia 🇺🇸 in 09/25— inspiring discussions on global oncology initiatives, leadership, and equity in cancer care. 🌍💪 #ASCO #GlobalOncology #IAC

Proud to share our commentary “Experience of AL in Latin America” (Blood Global Hematology2025), highlighting growing awareness of light-chain amyloidosis and the need for better access to diagnostics and therapies in the region. @erivaserra @CamiPenaO 🔗 doi.org/10.1016/j.bglo…

📌 EBMT 2025 Indications for HCT & CAR-T (Practice Recommendations) 🔹 General Principles •EBMT updates every 4–5 yrs; this is the 9th special report. •Decisions must balance disease risk, HCT risk, NRM, non-HCT options, and patient QoL. •Registry harmonization & JACIE standards emphasized. •Rise in CAR-T & gene therapy reshaping transplant indications. ⸻ 🧬 Acute Myeloid Leukemia (AML) •Allo-HCT in CR1 → indicated for adverse risk & most intermediate risk (per ELN/NCCN). •Not indicated in favorable risk unless MRD+. •Mutations mandating HCT: ASXL1, BCOR, EZH2, RUNX1, SRSF2, TP53, etc. •RIC vs MAC: RIC ↓NRM, MAC ↓relapse (best in MRD+). ⸻ 🧪 Acute Lymphoblastic Leukemia (ALL) •Ph+ ALL: HCT standard in CR1 (imatinib + chemo), but role evolving with 3rd gen TKIs + mAbs. •Ph− ALL: HCT indicated if MRD >0.01% after 3 blocks or high-risk cytogenetics (e.g., KMT2A, low hypodiploidy). •CAR-T: ZUMA-3, FELIX → >70% CR in R/R B-ALL; consolidation allo-HCT may be needed post CAR-T relapse. ⸻ 🧬 Chronic Myeloid Leukemia (CML) •TKIs remain SOC; HCT only if failing ≥3rd gen TKI, T315I mutation, or intolerance. •Indicated in advanced phase or progression. ⸻ 🧩 Myeloproliferative Neoplasms (MF focus) •HCT = only curative option. •Indicated if Int-2/high DIPSS or high MIPSS70/MYSEC-PM. •Splenomegaly >5 cm → spleen-directed therapy (JAKi) pre-HCT. ⸻ 🧩 MDS & CMML •MDS: HCT for IPSS-R high/very high or IPSS-M moderate-high/high/very high. •Lower risk → delayed HCT unless progression or high-risk mutations. •CMML: HCT in CPSS-Mol high, or Int-2 + extra risk factors (splenomegaly, hyperleukocytosis). ⸻ 🧬 CLL •Novel agents (BTKi + BCL2i) changed landscape. •HCT only for double-refractory patients (failed BTKi + venetoclax). •Allo-HCT considered for Richter’s transformation (clonally related). ⸻ 🩸 Lymphomas •LBCL: CAR-T (axi-cel/liso-cel) is 2nd line SOC for primary refractory/early relapse. Auto-HCT still option for late relapse. •FL: Auto-HCT in POD24 or transformed FL; CAR-T (axi-cel, tisa-cel) approved from 3rd/4th line. •MCL: Bruton’s TKIs first line; CAR-T after ≥2 lines (esp. BTKi failure). •PTCL/CTCL: Allo-HCT curative in R/R; auto-HCT for CR1 in selected subtypes. •HL: Auto-HCT SOC in R/R; allo-HCT after failed BV & CPI; CAR-T investigational. ⸻ 🧩 Multiple Myeloma (MM) •Auto-HCT still SOC frontline in fit patients. •Allo-HCT reserved for high-risk in trials. •CAR-T (ide-cel, cilta-cel) → outstanding efficacy in R/R MM (PFS ~55% @27mo). ⸻ 🧬 Non-malignant & Solid Tumors •SAA: MSD-allo-HCT is SOC ≤40 yo; MUD considered in young (<18). •Hemoglobinopathies: •Thalassemia: HCT if no severe organ damage. •SCD: HCT if severe phenotype & no severe organ damage. •Gene therapy emerging as alternative. •Solid tumors: HCT rarely indicated; CAR-T under evaluation (gliomas, sarcomas). ⸻ 🎯 Exam Pearls for Fellows •AML: Allo-HCT in CR1 adverse/intermediate (MRD+). •ALL: MRD >0.01% = HCT indication. •LBCL: CAR-T now 2nd line SOC (axi-cel/liso-cel). •CLL: Only “double-refractory” = HCT. •MDS/CMML: Use IPSS-M / CPSS-Mol for decision. •SAA: Age >40 → outcomes decline sharply. ⸻ 🔗 Full reference: Greco R, Ruggeri A, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplant. 2025. DOI: 10.1038/s41409-025-02701-3 ⸻ Credits for sharing to Dr. Ahmed Alahmadi ⸻ #HCT #CART #EBMT2025 #HemOnc #Transplant

Learn about the status quo of #CARTcells in LATAM and my predictions for the near future 🔮 no charge 👇🏻

Fascinating conversations- brilliant ideas- 100 percent member engagement.. and most importantly doing all that w smile on face (even when one may have braces😬) and laughter in the room… this has been the best committee experience ever… 🥳👏🙌🎀

ASCT vs CAR-T in CR for R/R DLBCL @TheEBMT #18ICML: no diff OS, PFS, relapse or NRM in propensity matched model. Important findings for areas in which CAR-T is not available. #lymsm #bmtsm

My top 5 picks for plasma cell disorders abstracts at #ASCO25 #mmsm in no order of preference: 1) 7505: Trispecific targeting BCMA/GPRC5D, this is by the far the most disruptive advance in early development! 2) 7507: Are we curing RRMM with BCMA CART? 3) 7508: Next Gen BCMA CART for AL Amyloidosis, one and done? 4) 7509: Extended Quad Therapy (Isa-KRd) for High Risk TE-NDMM in the GMMG-HD7 trial, is more better? 5) Tie 7512/7516: Dara-Quad, Bela-triplet for TI-NDMM - balance between efficacy and safety. I’ll comment more once the data are out! @mtmdphd @VincentRK @SagarLonialMD @RahulBanerjeeMD @mvmateos @NoopurRajeMD @Rfonsi1 @IMFmyeloma @theMMRF @HealthTree @MSKCancerCenter @MSK_DeptOfMed

Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies - The Lancet Infectious Diseases thelancet.com/journals/lanin…

@GuiperiniMD @LABMT2 Thank you Guilherme.

@julefranve @LABMT2 Congrats, Jule!

The Peruvian delegation. This is my first in-person congress. We had 3 e-posters with the Instituto Nacional de Enfermedades Neoplásicas as the only or lead Peruvian institution and also participated in 2 collaborative studies with the @LABMT2 in maintenance in MM and ASCT in HL.

Don’t forget to take a look on the e-posters on site or by the app! Our #ICOnic Lymphoma team is also present at #EBMT25 with the LWP

HSCT-TMA. Key points. #EBMT25 @Mohty_EBMT @Mohty_EBMT @TheIACH @FabioTorressav #IACHnews

Adenovirus infection management in HSCT patients #EBMT25 @UsuarezMD @Mohty_EBMT @TheIACH

We have 3 Peruvians studies: 1) MM, 2)Phi(+) ALl and 3) AML

This is probably the most important publication we have published for trainees and senior oncologists alike. This provides answers to almost every question you have about surrogate endpoints in oncology. This is a must-read for anyone with an interest in cancer trials. FREE!

Residency Life Hacks: Check out Stats, STAT! videos from @NEJMEvidence for quick explanations of fundamental statistical concepts. Explore these videos at nej.md/4ksfudH. Keep watching our feed for more ways to level up your intern year! #MatchDay2025

#AML remains a dismal disease with poor prognosis, particularly in the relapsed/refractory (R/R) setting. ow.ly/wnUR50VhJQ5 #immunobiologyandimmunotherapy #myeloidneoplasia